ATE516807T1 - Sensibilisierung von für chemotherapeutische mittel resistenten neoplastischen zellen durch reoviren - Google Patents

Sensibilisierung von für chemotherapeutische mittel resistenten neoplastischen zellen durch reoviren

Info

Publication number
ATE516807T1
ATE516807T1 AT02701122T AT02701122T ATE516807T1 AT E516807 T1 ATE516807 T1 AT E516807T1 AT 02701122 T AT02701122 T AT 02701122T AT 02701122 T AT02701122 T AT 02701122T AT E516807 T1 ATE516807 T1 AT E516807T1
Authority
AT
Austria
Prior art keywords
reoviruses
sensitization
chemotherapeutic agents
neoplastic cells
cells resistant
Prior art date
Application number
AT02701122T
Other languages
English (en)
Inventor
Matthew Coffey
Bradley Thompson
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Application granted granted Critical
Publication of ATE516807T1 publication Critical patent/ATE516807T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02701122T 2001-02-20 2002-02-19 Sensibilisierung von für chemotherapeutische mittel resistenten neoplastischen zellen durch reoviren ATE516807T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27036301P 2001-02-20 2001-02-20
PCT/CA2002/000201 WO2002066040A2 (en) 2001-02-20 2002-02-19 Sensitization of chemotherapeutic agent resistant neoplastic cells with reovirus

Publications (1)

Publication Number Publication Date
ATE516807T1 true ATE516807T1 (de) 2011-08-15

Family

ID=23031034

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02701122T ATE516807T1 (de) 2001-02-20 2002-02-19 Sensibilisierung von für chemotherapeutische mittel resistenten neoplastischen zellen durch reoviren

Country Status (16)

Country Link
US (5) US7264798B2 (de)
EP (2) EP1361884B1 (de)
JP (3) JP4951194B2 (de)
AR (1) AR035227A1 (de)
AT (1) ATE516807T1 (de)
AU (2) AU2002234453B2 (de)
BR (1) BR0207691A (de)
CA (1) CA2437468C (de)
DK (1) DK1361884T3 (de)
ES (1) ES2367768T3 (de)
HK (1) HK1060520A1 (de)
IL (2) IL157167A0 (de)
MX (1) MXPA03007486A (de)
NZ (2) NZ537709A (de)
WO (1) WO2002066040A2 (de)
ZA (1) ZA200305875B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
AR035227A1 (es) * 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
BR0311448A (pt) 2002-05-10 2005-03-15 Oncolytics Biotech Inc Métodos para sensibilizar uma célula neoplástica a radiação, para tratar ou melhorar um tumor em um paciente, e para impedir um tumor de desenvolver resistência à radiação em um paciente
MXPA05011462A (es) * 2003-04-25 2005-12-15 Wellstat Biologics Corp Tratamiento de carcinomas hepatocelulares utilizando virus terapeuticos.
MXPA05013879A (es) 2003-06-18 2006-06-27 Genelux Corp Virus de la vaccinia recombinantes modificados y otros microorganismos, y usos de los mismos.
JP5170741B2 (ja) * 2004-04-27 2013-03-27 ウェルスタット バイオロジクス コーポレイション ウイルスおよびカンプトテシン類を使用する癌の処置
WO2005112966A1 (en) * 2004-05-21 2005-12-01 Orison Biotechnology Inc. Combined therapy with a herbal extract and a reovirus for killing neoplastic cells in a subject
AU2006270297B2 (en) * 2005-07-14 2013-01-17 Wellstat Biologics Corporation Cancer treatment using viruses, fluoropyrimidines and camptothecins
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
EP1917351A4 (de) * 2005-08-01 2009-12-16 Univ Technologies Int Abgeschwächtes reovirus
CA2630833C (en) * 2005-11-24 2015-01-06 Aicuris Gmbh & Co. Kg Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer
WO2008100292A2 (en) 2006-10-16 2008-08-21 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
WO2008150496A2 (en) * 2007-05-31 2008-12-11 Genelux Corporation Assay for sensitivity to chemotherapeutic agents
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
US20090162288A1 (en) * 2007-07-18 2009-06-25 Nanhai Chen Use of modified vaccinia virus strains in combination with a chemotherapeutic agent for use in therapeutic methods
WO2009052617A1 (en) * 2007-10-22 2009-04-30 Oncolytics Biotech Inc. Treatment regime for proliferative disorders
EP2244714A4 (de) * 2008-02-08 2012-06-06 Poniard Pharmaceuticals Inc Verwendung von picoplatin und bevacizumab zur behandlung von kolorektalkarzinom
WO2009139921A2 (en) * 2008-05-16 2009-11-19 Genelux Corporation Microorganisms for preventing and treating neoplasms accompanying cellular therapy
WO2009143468A1 (en) * 2008-05-22 2009-11-26 Uti Limited Partnership Tumor suppressor-based susceptibility of hyperproliferative cells to oncolytic viral therapy
TW200950777A (en) * 2008-05-27 2009-12-16 Oncolytics Biotech Inc Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
US20110086005A1 (en) * 2008-05-27 2011-04-14 Oncolytics Biotech Inc. Modulating interstitial pressure and oncolytic viral delivery and distribution
AU2013204555A1 (en) * 2012-04-30 2013-11-14 Oncolytics Biotech Inc. Protecting modified viruses from neutralizing antibodies using the reovirus sigma 1 protein
CA3003133C (en) 2014-10-24 2020-09-15 StemImmune, Incorporated Combination immunotherapy approach for treatment of cancer
CN104881181B (zh) * 2015-05-27 2019-07-26 联想(北京)有限公司 显示方法及电子设备
US11655455B2 (en) 2018-11-06 2023-05-23 Calidi Biotherapeutics, Inc. Enhanced systems for cell-mediated oncolytic viral therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0931830B1 (de) 1993-02-16 2001-03-07 Onyx Pharmaceuticals, Inc. Cytopatische Viren zur Therapie und Prophylaxe der Neoplasie
PT1314431E (pt) 1993-04-30 2008-10-24 Wellstat Biologics Corp Composições purificadas de vírus da doença de newcastle
US5776743A (en) * 1994-09-06 1998-07-07 La Jolla Cancer Research Foundation Method of sensitizing tumor cells with adenovirus E1A
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
EP1905304A3 (de) 1997-10-09 2008-08-13 Wellstat Biologics Corporation Behandlung von Neoplasmen mit Viren
US6428968B1 (en) * 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
JP2003514024A (ja) * 1999-11-12 2003-04-15 オンコリティクス バイオテク，インコーポレーテッド 細胞増殖性疾患の治療のためのウイルス
AR035227A1 (es) * 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
US7163678B2 (en) * 2002-11-07 2007-01-16 Oncolytics Biotech Inc. Reovirus for the treatment of ral-mediated cellular proliferative disorders

Also Published As

Publication number Publication date
JP2008120837A (ja) 2008-05-29
EP1361884A2 (de) 2003-11-19
US8658158B2 (en) 2014-02-25
WO2002066040A3 (en) 2003-05-30
US20080031851A1 (en) 2008-02-07
JP2012072192A (ja) 2012-04-12
US20110243890A1 (en) 2011-10-06
AU2002234453B2 (en) 2007-05-17
US7608257B2 (en) 2009-10-27
ES2367768T3 (es) 2011-11-08
CA2437468C (en) 2007-06-19
IL157167A (en) 2014-05-28
US20130017172A1 (en) 2013-01-17
NZ527399A (en) 2005-09-30
IL157167A0 (en) 2004-02-08
ZA200305875B (en) 2004-07-30
JP2004517966A (ja) 2004-06-17
CA2437468A1 (en) 2002-08-29
EP1361884B1 (de) 2011-07-20
MXPA03007486A (es) 2003-12-08
DK1361884T3 (da) 2011-10-03
JP4951194B2 (ja) 2012-06-13
EP2314301A2 (de) 2011-04-27
BR0207691A (pt) 2006-01-31
WO2002066040A2 (en) 2002-08-29
US20100021432A1 (en) 2010-01-28
NZ537709A (en) 2006-11-30
US20020168344A1 (en) 2002-11-14
AU2007207860B2 (en) 2008-10-23
AU2007207860A1 (en) 2007-09-06
HK1060520A1 (en) 2004-08-13
WO2002066040A8 (en) 2003-03-20
US7264798B2 (en) 2007-09-04
EP2314301A3 (de) 2011-08-17
AR035227A1 (es) 2004-05-05
US7964187B2 (en) 2011-06-21

Similar Documents

Publication Publication Date Title
ATE516807T1 (de) Sensibilisierung von für chemotherapeutische mittel resistenten neoplastischen zellen durch reoviren
DE60318920D1 (de) Induktion von Insulin-produzierende Zellen
DE60216708D1 (de) Speicherzellestruktur
DE60311164D1 (de) Bausatz für zusammenbau von Strukturen
DK1370556T3 (da) Metalloproteinaseinhibitorer
DE60103197D1 (de) Zusammensetzungen für Säurebehandlung von Bohrlöchern
NO20034025D0 (no) Metalloproteinaseinhibitorer
NO20034027L (no) Metalloproteinaseinhibitorer
DE60216503D1 (de) Verringerung von reaktionsnebenprodukten in polycarbonatharzen
DE50213681D1 (de) Wässrige Lösung von Ascorbinsäure
SE0400389L (sv) Resursdelande celler
DE10194033D2 (de) Gehäuse für elektrochemische Zellen
DE602004004943D1 (de) Reinigung von Metallkohlenwasserstoff
ATE517983T1 (de) Entfernung von neoplastischen zellen aus gemischten zellulären zusammensetzungen mittels viren
ATE474040T1 (de) Entfernung von ras-vermittelten neoplastischen zellen aus gemischten zellulären zusammensetzungen mittels reoviren
NO20034182L (no) Kjemiske forbindelser
DE60128346D1 (de) Elektrolytische lösung für elektrolytkondensator und diese verwendender elektrolytkondensator
DE60308613D1 (de) Mischungen von Nicht-Azo-Dispersfarbstoffen
DE60201084D1 (de) Herstellung von cyclischen esteroligomeren
FR2841883B1 (fr) Butoir pour quai
DE50015345D1 (de) Realisierung von zusätzlichen funktionen für leistungsmerkmale aufweisende teilnehmeranschlüsse
DE60326321D1 (de) Herstellungsverfahren von Farbstoffen
ATE429214T1 (de) Mikrokapseln für die verzögerte kontrollierte freisetzung von perindopril
ATE474824T1 (de) Herstellung von olefinen
DE60223086D1 (de) Modifikator für polymilchsäure und den modifikator enthaltende polymilchsäurezusammensetzung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties